Innovative Science Meets Acceleration™

Catherine Pearce, M.B.A., D.HSc., is an innovative professional with over 25 years of experience focused on the biotech industry at various organizations. She founded JucaBio in April 2023.

Dr. Pearce created and led the clinical stage biotech function of CinCor Pharma, Inc., from its formation through its acquisition by AstraZeneca for up to $1.8 billion in early 2023. Prior to CinCor Pharma, she was co-founder and served as the Chief Operating Officer of CinRx Pharma, LLC where she was instrumental in building 6 portfolio companies including CinCor Pharma.  Additionally, she has served as Vice President, Strategic Alliances at Medpace and Vice President, Research and Development at Teva Pharmaceutical Industries Ltd. She sits on a variety of corporate boards and provides strategic consulting for several biotech companies.

Dr. Pearce has demonstrated key skills in Clinical Project Management, R&D, and Business Development. She has successfully led many drug development programs, brought multiple marketed products to fruition, and established strategic alliances. Her strategic leadership and expertise have been pivotal in achieving major milestones, including the acquisition of CinCor Pharma by AstraZeneca. Additionally, Dr. Pearce's expertise in biotech has helped numerous companies establish successful drug development and operational frameworks.

Dr. Pearce holds a B.S. and an M.B.A. from Xavier University and a Doctor of Health Sciences from Nova Southeastern University. In her personal life, she enjoys college basketball games, cooking big Italian meals, and golfing with her husband.

Dr. Bill Marshall is a proficient clinician scientist with over 35 years of experience focused on drug development at various organizations.

Prior to JucaBio, Dr Marshall served as VP, Medical at CinCor leading the development of baxdrostat prior to its acquisition by AstraZeneca. Additionally, Dr. Marshall created and led the translational pharmacology division at Merck, a Fortune 500 pharmaceutical company, and spearheaded drug development from its formation through the design and oversight of Phase 1 and Phase 1b/proof of concept studies, culminating in several successful drug development programs. He has also held increasing leadership positions at Alexion, Allovir, reSTORbio Pharma, and others. He also worked as an Instructor of Medicine at Harvard Medical School and later as an Associate Professor of Medicine at the University of Massachusetts Medical School.

Dr. Marshall has demonstrated key skills in clinical development strategies, regulatory compliance, and team leadership. He has successfully overseen Phase 1 through Phase 3 multicenter and/or multinational trials in various indications such as neurology, endocrine/hypertension, aging, autoimmunity, and infectious disease. His strategic clinical development and leadership have been pivotal in achieving major milestones, including several regulatory approvals. Additionally, Dr. Marshall's expertise in scientific discussions and publication strategies has helped numerous pharmaceutical companies establish efficient clinical frameworks.

Dr. Marshall holds a B.S. from Harvard University and a medical degree from Columbia University, College of Physicians and Surgeons. In his spare time, Bill chases after his six-year-old “puppy” DeeDee who is a half Shih Tzu, half Golden Doodle and all attitude.

Justin R. Thompson, MS is an experienced professional with over 20 years of business development and strategic investments in the life sciences and venture capital industry. Justin founded JucaBio in April 2023.

Justin led the business development function of CinCor Pharma, Inc., a clinical-stage biotech, from its formation through the in-licensing of baxdrostat from Roche, culminating in its acquisition by AstraZeneca for up to $1.8 billion in early 2023. Justin, in conjunction with Dr. Pearce, led the in-licensing of baxdrostat in 2019.  Prior to CinCor, he served as the Chief Business Officer at CinRx Pharma, LLC, leading additional licensing and venture transactions.  He was also a Principal investor at CincyTech, LLC, a public-private seed-stage investor focused on high-growth life science and technology companies.

Justin has demonstrated key skills in business development, strategic investments, and leadership. He has successfully led the in-licensing of key assets, managed strategic partnerships, and driven significant growth and acquisitions. His strategic vision and leadership have been pivotal in achieving major milestones, including successful acquisitions and the establishment of robust investment frameworks. Additionally, Justin's expertise in strategic investments has helped numerous life science companies establish strong financial and operational foundations.

Justin holds an M.S. from the University of Cincinnati and a B.S. from Washington University in St. Louis. In his personal life, he enjoys spending time with his family and almost anything outdoors.

Jack Greene is a dedicated professional with over 25 years of experience focused on drug substance, drug product, and CMC regulatory teams at various organizations.

Jack created and led the CMC function of CinCor Therapeutics, a clinical-stage biotech, through the complex manufacturing process of baxdrostat, culminating in its acquisition by AstraZeneca. Prior to CinCor, he served as Head of CMC at Anagram Therapeutics, and held positions at Allena Pharmaceuticals, Alcresta Therapeutics, Alnara (acquired by Eli Lilly & Co), Altus Pharmaceuticals, Alkermes, Genzyme, and Serono.

Jack has demonstrated key skills in CMC regulatory, process development of both NCE/NME and biologics drug substances, and formulation development of oral, parenteral, and inhalation drug products. He has successfully managed analytical development/QC and characterization, integrated commissioning and qualification of new manufacturing plants, and the design of integrated plant-wide process control systems. His strategic design, implementation, and validation of enterprise-level computer systems, including LIMS, SCADA, ERP/MRP, eQMS, and CMMS, have been pivotal in achieving major milestones. Additionally, Jack's expertise in these areas has helped numerous pharmaceutical companies establish quality manufacturing frameworks.

Jack is an Organic Chemist by training and lives in Boston with his family.  In his spare time, he fixes broken things, cleans up messes, and combines these skills to restore vintage automobiles.

Andrea Ledford, CPA, is a devoted professional with over 20 years of experience focused on accounting and financial management at various organizations.

Andrea created and led the accounting function of CinCor Pharma, Inc., a clinical-stage biotech, from its formation through IPO, culminating in its acquisition by AstraZeneca for up to $1.8 billion in early 2023. Prior to CinCor, she served as the Controller at CinRx Pharma, LLC, and Zipscene, a software development company. She also worked as an auditor at PWC and consulted for several biotech and startup companies.

Andrea has demonstrated key skills in financial strategy, investment strategy, GAAP and SOX compliance, leadership. She has successfully managed financial operations, led companies through significant growth phases, and ensured compliance with industry standards. Her strategic financial planning and leadership have been pivotal in achieving major milestones, including successful IPOs and acquisitions. Additionally, Andrea's expertise in consulting has helped numerous startups establish robust financial frameworks.

Andrea holds an M.S. in Accounting and a B.S. in Business Administration from the University of North Carolina at Chapel Hill. In her personal life, she has a love for the theatre and has served on boards and directed several productions for various children’s theatres.

James Hui, PhD brings over 30 years of experience in preclinical and clinical drug development. He oversees pharmacokinetics, drug metabolism, bioanalytical chemistry, toxicology, and clinical pharmacology activities. Prior to joining JucaBio, Dr. Hui served at large pharma and biotech organizations, including AstraZeneca, Alexion, Achillion Pharmaceuticals, Sanofi, Genzyme, Gilead Sciences, Solvay Pharmaceuticals, and Abbvie, where he led preclinical and clinical drug development operations.

Throughout his career, he has effectively organized, led, and developed productive R&D groups. He has contributed to over 20 IND applications and 10 NDA/BLA submissions, in addition to many regulatory submissions worldwide. His expertise spans treatments for viral infectious diseases, rare complement-related pathologies, precision oncologic and cardiovascular indications.

Dr. Hui holds a B.S. in Pharmacy from the University of Toronto and a Ph.D. from The Ohio State University. In his spare time, James enjoys traveling and exploring interesting new cuisines.

Jane H. Chamberland brings over 20 years of expertise in quality assurance and compliance within the pharmaceutical, medical device, and combination product industries. She leads the Quality Assurance Unit and provides support through various stages of development including designing and implementing robust quality management systems. Prior to joining JucaBio, Jane built a distinguished career with companies like CinCor Pharma, T2 Biosystems, TARIS Biomedical, Sepracor, and Alkermes, where she led quality assurance teams and prepared organizations for FDA and international regulatory inspections.

Throughout her career, she has successfully transitioned quality systems to fully electronic platforms, fostered continuous improvement, and mentored cross-functional teams to achieve operational excellence. Partnering with regulatory affairs, she has supported regulatory submissions, including INDs and NDAs. Dedicated to enhancing product integrity and ensuring compliance with U.S. and international standards, Jane delivers quality-focused solutions that align with organizational goals and drive success.

Jane holds a B. A in Biology from Bridgewater State University. In her personal life, Jane is an automotive restoration enthusiast.

Carie Masoner brings over 25 years of experience in the pharmaceutical, biotech, and Clinical Research Organization industries. She coordinates program management initiatives, providing support through various stages of development including clinical operations and regulatory affairs. Prior to joining JucaBio, Carie held positions of increasing leadership and responsibility, including Head of Global Regulatory and Scientific Affairs at CTI Clinical Trials & Consulting, Head of Regulatory and Medical Writing at Firma Clinical Research, Associate Director of Regulatory Affairs at Xanodyne Pharmaceuticals, Senior Clinical Trial Manager of Product Development at Xanodyne Pharmaceuticals, and Clinical Trial Manager and Lead CRA at Medpace.

Throughout her career, she has managed multiple global clinical programs, led the development and maintenance of Investigational New Drug (IND) dossiers, and successfully contributed to and submitted over 12 successful NDAs and BLAs. She has experience across therapeutic areas including metabolic diseases, pulmonary, infectious disease, oncology, transplant, pain, and rare diseases. The combination of her experience in Clinical Operations and Regulatory Affairs has provided her with a deep understanding of the complexity and needs in drug development, allowing her to excel at developing teams and operationalizing programs.

Carie holds a B.S. in Human and Consumer Science from Ohio University. In her personal life, Carie enjoys traveling, reading, playing games of skill and spending time with her family.

Kenny Kamineni brings 20 years of experience in the pharmaceutical, biotech and medical device industries.  He oversees and directly manages CROs, clinical vendors and clinical studies across all Phases of Drug Development.  Prior to joining JucaBio, Kenny held positions in clinical operations within the rare disease and cardiovascular field, including Associate Director, Clinical Operations at AlloVir, Associate Director/Sr. Clinical Trial Manager at Ascendis Pharma, and Sr. CRA at St. Jude Medical. Throughout his career, with experience from both the clinical site and sponsor level, Kenny has successfully operationalized and implemented strategies in successful clinical trial conduct.

Kenny holds a Bachelor of Medicine & Bachelor of Surgery (MBBS) from Kempegowda Institute of Medical Sciences, Bangalore, India. In his free time, Kenny enjoys travelling the world, trying new delicacies, and playing with his dog, Daisy, a very energetic husky.

Shawn Grant brings over 25 years of spearheading IND enabling program strategies and expanding indications for drug pipelines. His collaborative spirit in partnering with CROs and academic institutions has led to the design of pivotal experiments that align with our mission. He leads the non-clinical phase of drug development through various stages of development including proof of concept and GLP non-clinical studies. Shawn is an expert in in lung development and airway diseases and held positions of increasing responsibility at Airway Therapeutics including Director, Nonclinical Development. Prior to joining the pharmaceutical industry, Shawn served at the Department of Pulmonary Biology at Cincinnati Children’s Hospital Medical Center, where he focused on Surfactant Protein D, as well as surfactant metabolism and function.

Throughout his career, he has effectively coordinated and led R&D projects, overseeing aspects such as staffing, research, and budgeting. He has also collaborated with various researchers and institutions, contributing to multiple peer-reviewed publications stemming from each project.

Shawn holds a B.S. in Biology from the University of Cincinnati and a Micro-master’s degree in project management from the Rochester Institute of Technology. In his personal life, Shawn enjoys running, skiing, camping, and traveling.

Madie Segna brings a strong background in clinical operations and project management. She coordinates program management initiatives, providing support through various stages of development including clinical operations, clinical pharmacology, nonclinical studies, and business development.

Madie interacts with both internal and external stakeholders involved in clinical trials and nonclinical studies, overseeing the activities of vendors, CROs, and site personnel. Her ability to drive timelines and budgets for key functional deliverables is highly valued, and she collaborates closely with the Chief Medical Officer and Clinical Leadership Team to manage the Scientific Advisory Board and multiple Key Opinion Leaders. Madie also plays a key role in business development and due diligence activities, directly supporting the CEO and CBO by coordinating strategic meetings, managing data rooms and facilitating asset evaluation.

Prior to her current role, Madie worked at Medpace in Cincinnati, OH, where she held several positions, including Lead Clinical Research Project Coordinator. She specialized in cardiovascular, renal, metabolic, and medical device studies.

Madie holds a B.S in Biology from Xavier University. In her spare time, Madie enjoys traveling, watching reality tv, and playing golf.